IHS FormWeb
Approved Formulary
Search by name
Search by class
Browse alphabetically
Select...
NUM
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
High Alert
Restricted Medications
Renal Adjustment Policy
Therapeutic Interchange Policy
Hazard.Drug Handling(USP 800)
Hazardous Waste
Chemotherapy
IV to PO Conversion Policy
Black Box Warnings
Look-Alike/Sound-Alike
REMS
Staff Telephone Numbers
Webpage Links
Add Formweb to your mobile device
Android
iOS
Home
QuickStart
Admin
IHS FormWeb
Approved Formulary
Search by name
Additional search options
Search by class
Browse alphabetically
Select...
NUM
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
High Alert
Restricted Medications
Renal Adjustment Policy
Therapeutic Interchange Policy
Hazard.Drug Handling(USP 800)
Hazardous Waste
Chemotherapy
IV to PO Conversion Policy
Black Box Warnings
Look-Alike/Sound-Alike
REMS
Staff Telephone Numbers
Webpage Links
Search results for:
oseltamivir
oseltamivir
Brand names:
Tamiflu
Form
Strength
CAPSULE, ORAL
30 mg; 45 mg; 75 mg
Display
Neuramindase Inhibitors
Class:
081828
Medication comments:
Per policy, these drugs are subject to renal dosing adjustments by pharmacy.
Renal Dosing Program
View all
Generic + Route
(Brand)
• Indications
Usual Adult Dose
Comments
Renal Dosage Adjustments
oseltamivir
PO
(
Tamiflu
©
)
• Prophylaxis
75 mg q24h
x 10 days
CrCl > 60: No adjustment necessary
CrCl 30-60: 30 mg q24h
CrCl ≤ 30: 30 mg q48h
ESRD/HD: not recommended (not studied)
oseltamivir
PO
(
Tamiflu
©
)
• Treatment
75 mg q12h
x 5 days
(start within 48 hrs
of onset)
CrCl > 60: No adjustment necessary
CrCl 30-60: 30 mg q12h
CrCl ≤ 30: 30 mg q24h
ESRD/HD: not recommended (not studied)
Last updated:
May. 24, 2021
Renal Adjustment Policy
oseltamivir subject to adjustments by pharmacy.
UpToDate
FDA DailyMed Package Insert
MedLinePlus (Patient Information)
MSDS Online
(Brand)
• Indications
Comments
(Tamiflu©)
• Prophylaxis
x 10 days
CrCl 30-60: 30 mg q24h
CrCl ≤ 30: 30 mg q48h
ESRD/HD: not recommended (not studied)
(Tamiflu©)
• Treatment
x 5 days
(start within 48 hrs
of onset)
CrCl 30-60: 30 mg q12h
CrCl ≤ 30: 30 mg q24h
ESRD/HD: not recommended (not studied)